Abcam, ab313646, Anti-EGFRvIII antibody [EPR28380-83]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal EGFR antibody. Suitable for WB, IP, Flow Cyt, IHC-P, ICC/IF and reacts with Transfected cell lysate - Human, Human, Transfected cell line - Human, Transfected cell line samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28380-83,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IP, ICC/IF, Flow Cyt, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EGFR VIII also known as EGFRvIII EGFR of 83 or 83 EGFR is a mutant form of the epidermal growth factor receptor (EGFR) with a molecular weight of approximately 145 kDa. This variant results from a deletion of exons 2 to 7 in the EGFR gene which produces a truncated protein that lacks a portion of the extracellular ligand-binding domain. The EGFRvIII does not bind ligands and is constitutively active. It is often expressed in cancer cells particularly in glioblastomas and some other solid tumors but not in normal tissues.
Biological function summary
EGFRvIII modifies signaling pathways that promote cell survival and proliferation. It is a part of cell membrane-based complexes interacting with proteins like PI3K and Src which helps in activating downstream signaling cascades. This constitutive signaling leads to increased oncogenic potential allowing the cells to thrive in uncontrolled manner contributing to tumor progression and resistance to conventional therapies.
Pathways
EGFRvIII participates in key signaling pathways such as the PI3K/AKT pathway and the RAS/RAF/MEK/ERK pathway. These pathways are important in transmitting signals from receptor tyrosine kinases to the cell nucleus. EGFRvIII links with proteins like AKT and ERK to drive processes that control growth and survival. The dysregulation of these pathways due to EGFRvIII activity can result in enhanced proliferative and survival signals in cancer cells.
EGFRvIII is strongly associated with glioblastoma and non-small cell lung cancer. In these conditions EGFRvIII expression correlates with poor prognosis and an aggressive tumor phenotype. The presence of EGFRvIII often accompanies other oncogenic proteins such as PTEN whose loss of function can amplify the oncogenic signaling of EGFRvIII. As a result targeting EGFRvIII represents a potential therapeutic intervention in such aggressive cancer types.